Conference Reports for NATAP

EASL 46th Annual Meeting March 30th - April 3rd 2011 Berlin, Germany Back

New Approach in HBV & HCV: Gilead's TLR 7 Agonist GS-9620 at EASL       Therapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees - (04/07/11)   Anti-Viral Efficacy and Induction of an Antibody Response Against Surface Antigen with the TLR7 Agonist GS-9620 in the Woodchuck Model of Chronic HBV Infection - (04/07/11)   Preclinical Characterization of GS-9620, A Potent and Selective Oral TLR7 Agonist - (04/06/11)   A Phase-I, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Escalating Oral Doses of GS-9620 In Healthy Subjects - (04/06/11)